Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT06926335
Active, not recruiting Observational

Oncological Safety of Oncoplastic Breast Surgery in Multicentric Breast Cancer

NCT06926335 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Observational
Started
2025-03-19
Last updated
2025-04-17

Condition(s) studied

Safety of Breast Coservative Multicenteric Breast CancerBreast NeoplasmsBreast CancerMulticentric

Investigational drug(s) / intervention(s)

Breast consevative surgery

Breast consevative surgery: plastic surgery principles within the context of sound oncological resection. Volume-reducing or volume- replacing methods are utilised to optimise postoperative appearances whilst prioritizing negative margin resection, supported by prompt adjuvant therapy

Study summary

The purpose of the study is to evaluate Oncological safety of oncoplastic breast surgery in multicentric breast cancer

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Female patients with multicentric breast cancer * Female Patient aged from 18 to 65 years old * Patients who are fit for general anesthesia. * Patients who provide a written informed consent. * Patient who agree to provide short term outcome data and agree to provide contact information to provide contact information Exclusion Criteria: * Female patients less than 20 years old * Stage 4 breast cancer * Patients who are contraindicated for radiotherapy * Pregnant patients in first trimester * Patient with inflammatory carcinoma

Primary outcome measure(s)

  • To evaluate Oncological safety of oncoplastic breast surgery in multicentric breast cancer — 5 years
    Number of multicentric breast cancer who underwent breast conservative surgery with no recurrance

Trial sites (1)

FacilityCityRegionStatus
Assuit University Asyut Egypt

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon
Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Intraoperative Lidocaine Infusion Starting soon

Other trials for the same condition

Shoulder Denervation for Post Mastectomy Irradiation Shoulder Pain Recruiting
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects Recruiting
Male Breast Cancer: Understanding the Biology for Improved Patient Care Active, not recruiting
Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients Recruiting
Prospective Comparative Study of Hypofractionated Adjuvant Radiotherapy in 2 Virsus 3 Weeks in Breast Cancer Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06926335 on ClinicalTrials.gov ↗ ← All trials in Egypt